Curcuminoid
Phase 1Small molecule
Curcuminoid is one of 41 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Truphylline
TThe Searle Company Limited Pakistan
Phase 3
Nicotinamide Treatment
AAssistance Publique - Hôpitaux de Paris
Phase 3
Crestor
AstraZenecaPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Proamatine
TakedaPreclinical
Lexapro
AbbViePreclinical
Lescol
NovartisPreclinical
Golytely
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Kidney Injury1 trial
Curcuminoids and Contrast-induced Acute Kidney Injury
Completed·—·Phase 1·NCT04890704·96 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Curcuminoid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- LLisa Flowers